Global ovarian cancer treatment drugs market set to double, reaching $5.45 billion by 2033

From GlobeNewswire: 2024-05-13 14:00:00

The Global Ovarian Cancer Treatment Drugs Market is set to double in size from USD 2.50 billion in 2023 to USD 5.45 billion by 2033, with a 8.10% CAGR. Surgery and platinum-based chemotherapy are traditional treatments, while PARP inhibitors and anti-angiogenic therapy are becoming more popular, improving results for ovarian cancer patients.

The PARP inhibitors segment dominates the market, with drugs like olaparib and niraparib showing significant therapeutic effects. Targeted therapy is expected to hold the largest market share, offering precise treatment with fewer side effects. Intravenous drug delivery is growing significantly, ensuring quick distribution throughout the body.

North America leads the market, with advanced medical facilities and awareness driving growth. Asia-Pacific is expected to grow rapidly due to increased healthcare infrastructure development. Major players in the market include AstraZeneca, Pfizer, and GlaxoSmithKline, with recent developments such as AbbVie’s acquisition of ImmunoGen expanding treatment options. The study forecasts revenue growth globally and by region, segmenting the market by therapeutic class, treatment type, route of administration, and end-user.



Read more at GlobeNewswire: Global Ovarian Cancer Treatment Drugs Market Size To Exceed